

## **Dr Reddy's Laboratories Ltd.**

NYSE:RDY

### **Q4 FY07 and FY07 Financial Performance Review**

#### **Table of Contents**

##### *FY07 USGAAP*

Financial Snapshot	02
Revenue Mix	03
Active Pharmaceutical Ingredients	04
Generic Formulations	05
Branded Formulations	05
Other Businesses	07
Income Statement Highlights	07

##### *Q4 FY07 USGAAP*

Financial Snapshot	09
Revenue Mix	10
Income Statement Highlights	12

All figures in millions, except EPS

All dollar figures based on convenience translation rate of 1USD = Rs 43.10

### EXTRACT FROM THE UNAUDITED INCOME STATEMENT

	FY07			FY06			
Particulars	(\$)	(Rs.)	%	(\$)	(Rs.)	%	Growth %
<b>Total Revenues</b>	<b>1,510</b>	<b>65,095</b>	<b>100</b>	<b>563</b>	<b>24,267</b>	<b>100</b>	<b>168%</b>
Cost of revenues	794	34,220	53	288	12,417	51	176%
<b>Gross profit</b>	<b>716</b>	<b>30,876</b>	<b>47</b>	<b>275</b>	<b>11,850</b>	<b>49</b>	<b>161%</b>
Selling, General & Administrative Expenses	326	14,051	22	186	8,029	33	75%
R&D Expenses <sup>(1)</sup>	57	2,463	4	50	2,153	9	14%
Amortization Expenses	36	1,571	2	10	420	2	274%
Write down of Intangible	41	1,770					
Other operating (income)/expense net <sup>(2)</sup>	-2	(67)	0	-7	(320)	(1)	-79%
<b>Operating income before forex loss/(gain)</b>	<b>257</b>	<b>11,088</b>	<b>17</b>	<b>36</b>	<b>1,568</b>	<b>6</b>	<b>607%</b>
Forex Loss/ (Gain)	-3	(137)	0	3	126	1	NC
<b>Operating income/(loss)</b>	<b>260</b>	<b>11,225</b>	<b>17</b>	<b>33</b>	<b>1,442</b>	<b>6</b>	<b>678%</b>
Equity in loss of affiliates	1	63	0	2	88	0	-28%
Other expenses/(income) net	15	661	1	-12	(534)	(2)	NC
<b>Income before income taxes and minority interest</b>	<b>244</b>	<b>10,501</b>	<b>16</b>	<b>44</b>	<b>1,888</b>	<b>8</b>	<b>456%</b>
Income tax (benefit)/expense	27	1,177	2	6	258	1	356%
Minority interest	0	(4)	0	0	0	0	
<b>Net income</b>	<b>216</b>	<b>9,328</b>	<b>14</b>	<b>38</b>	<b>1,630</b>	<b>7</b>	<b>472%</b>
<b>DEPS</b>		<b>58.56</b>			<b>10.62</b>		
Exchange rate		43.10			43.10		
<b>Key Balance Sheet Items</b>							
	<b>As on 31st Mar 07</b>			<b>As on 31st Mar 06</b>			
Cash and cash equivalents	<b>431</b>	<b>18,588</b>		<b>227</b>	<b>9,788</b>		
Borrowings from banks (Short + Long)	<b>574</b>	<b>24,754</b>		<b>719</b>	<b>30,995</b>		
Accounts receivable, net of allowances	<b>174</b>	<b>7,519</b>		<b>111</b>	<b>4,802</b>		
Inventories	<b>175</b>	<b>7,546</b>		<b>160</b>	<b>6,895</b>		
Property, plant and equipment, net	<b>288</b>	<b>12,428</b>		<b>211</b>	<b>9,086</b>		

- (1) Income recognition under Generics R&D partnership with ICICI venture amounting to Rs 453 million in FY 07 and Rs. 405 million in FY 06. R&D Expense reimbursed by Perlecan Pharma in FY07 at Rs. 373 million
- (2) Includes profit on sale of finished dosages facility at Goa amounting to Rs. 388 million in FY 06.
- (3) including restricted cash

## Revenue Mix by Segment

(in million)

	FY07 \$	FY07 INR	as a %	FY06 \$	FY06 INR	as a %	Growth %
<b>APIs</b>	<b>274</b>	<b>11,827</b>	<b>18</b>	<b>191</b>	<b>8,238</b>	<b>34</b>	<b>44</b>
India	48	2,075	18	53	2,296	28	-10
International	226	9,752	82	138	5,942	72	64
<b>Branded Formulations</b>	<b>286</b>	<b>12,319</b>	<b>19</b>	<b>230</b>	<b>9,926</b>	<b>41</b>	<b>24</b>
India	149	6,415	52	128	5,526	56	16
International	137	5,904	48	102	4,400	44	34
<b>Generics<sup>(1)</sup></b>	<b>771</b>	<b>33,224</b>	<b>52</b>	<b>94</b>	<b>4,056</b>	<b>17</b>	<b>719</b>
<b>Emerging Business</b>	<b>19</b>	<b>824</b>	<b>1</b>	<b>16</b>	<b>691</b>	<b>3</b>	<b>19</b>
<b>Custom pharmaceutical services<sup>(2)</sup></b>	<b>153</b>	<b>6,600</b>	<b>10</b>	<b>31</b>	<b>1,327</b>	<b>5</b>	<b>397</b>
<b>Others</b>	<b>7</b>	<b>301</b>	<b>0</b>	<b>1</b>	<b>29</b>	<b>0</b>	
<b>Total</b>	<b>1,510</b>	<b>65,095</b>	<b>100</b>	<b>563</b>	<b>24,267</b>	<b>100</b>	<b>168</b>

1. Includes betapharm revenues of Rs. 8,004 million in FY07 and Rs. 705 million in FY 06 (starting 3rd March)
2. Includes revenues from CPS business in Mexico of Rs. 5,397 million in FY 07 and Rs. 805 million in FY 06 (starting 31st December)

## Revenue Mix by Geography

(in million)

	FY07 \$	FY07 INR	As a %	FY06 \$	FY06 INR	as a %	Growth %
India	213	9,179	14	192	8,272	34	11
North America	657	28,337	44	92	3,984	16	611
Russia	83	3,584	6	62	2,676	11	34
Europe	344	14,839	23	100	4,326	18	243
Others	213	9,156	13	117	5,009	21	83
<b>TOTAL</b>	<b>1,510</b>	<b>65,095</b>	<b>100</b>	<b>563</b>	<b>24,267</b>	<b>100</b>	<b>168</b>

## Business Highlights

- Overall revenues at \$1.5 billion in FY07 as against \$563 million in FY06.
- Revenues at Rs 65 billion as against Rs 24 billion in FY06. YoY growth of 168%.
  - Revenues from international markets increased by 250% to Rs. 56 billion.
  - Revenues from India increased by 11% to Rs. 9 billion.
- Revenues excluding the contribution from authorized generics and acquisitions, increased by 58% to Rs 36 billion in FY07 from Rs 23 billion in FY06.
- Revenues from authorized generics contributed 24% and acquisitions contributed 21% respectively to total revenues in FY07.

- Revenues in branded formulations business increased by 24% to 12 billion in FY07 from Rs. 10 billion in FY06 driven by growth across key markets.
  - Revenues from international markets grew by 34% to Rs. 5.9 billion, driven by growth in Russia, Romania, Venezuela and CIS region.
  - Revenues from India grew by 16% to Rs. 6.4 billion, driven by growth in key brands.
- Revenues in the API business increased by 44% to Rs 11.8 billion in FY07 from Rs. 8.2 billion in FY 06 driven primarily by sales of sertraline, rabeprazole and ramipril.
- Revenues from custom pharmaceuticals services business increased to Rs 6.6 billion from Rs 1.3 billion in FY06. Even after excluding contributions from acquisitions, revenues grew from Rs. 522 million to Rs. 1,203 million, driven by growth in customer base and product portfolio.
- Revenues in Europe generics (including acquisition) at Rs 9.6 billion as against Rs 2.4 billion in FY06.

#### **Active Pharmaceutical Ingredients (APIs)**

- Revenues at Rs 11.8 billion as against Rs 8.2 billion in FY06. YoY growth of 44%
- Revenues outside India at Rs 9.8 billion as against Rs 5.9 billion in FY06. YoY growth of 64%; Growth across key international markets.
- Revenues in Europe increased by 47% to Rs. 2.1 billion in FY07 from Rs. 1.4 billion in FY06 primarily led by growth of key products of sertraline, finastride, losartan and ramipril.
- Revenues in India at Rs 2.1 billion as against Rs 2.3 billion in FY06. YoY decline of 10% primarily on account of decrease in sales of quinolones due to significant decline in prices.
- Revenues in rest of the world increased to Rs. 5.6 billion in FY07 from Rs. 2.9 billion in FY06 primarily driven by growth in key products of sertraline, rabeprazole and clopidogrel.
- Revenues in North America at Rs 2.0 billion in FY07 as against Rs 1.7 billion in FY06. This increase was on account of increase in sales of new products as well as key commercialized products such as naproxen sodium, naproxen and sertraline.
- The Company filed 23 US DMFs during the year taking the total filings to 104. The company also filed 11 DMFs in Canada, 9 DMFs in Europe and 26 DMFs in RoW including 6 in Japan and 5 in Turkey.

**API - Geographic Mix***(in million)*

	<b>FY07 \$</b>	<b>FY07 INR</b>	<b>As a %</b>	<b>FY06 \$</b>	<b>FY06 INR</b>	<b>as a %</b>	<b>Growth%</b>
North America	47	2,030	16	38	1,655	20	<b>23</b>
India	48	2,075	18	53	2,296	28	<b>-10</b>
Europe	48	2,089	18	33	1,421	17	<b>47</b>
ROW	131	5,633	48	66	2,866	35	<b>97</b>
<b>TOTAL</b>	<b>274</b>	<b>11,827</b>	<b>100</b>	<b>190</b>	<b>8,238</b>	<b>100</b>	<b>44</b>

**Generic Formulations**

- Revenues in this segment at Rs 33.2 billion as against Rs. 4.1 billion in FY06.
- North America contributed 71% to the total revenues & Europe (including betapharm) contributed 29%.
- In North America, revenues increased to Rs. 23.6 billion in FY07 from Rs. 1.6 billion in FY06. Combined revenues of simvastatin and finasteride (AG products) were at Rs. 15.8 billion. Fexofenadine launched in April contributed Rs. 2.4 billion and ondansetron launched in Dec 2006 (under 180 day exclusivity) contributed Rs. 2.9 billion in revenues during the year.
- In Europe revenues increased to Rs. 9.6 billion in FY07 from Rs. 2.4 billion in FY06.
  - Revenues from betapharm (Germany) were at Rs. 8,004 million in FY 07 as compared to Rs 705 million in FY 06, which represents 28 days of revenue starting 3<sup>rd</sup> March 2006.
  - Revenues from UK market decreased to Rs. 1.5 billion in FY 07 from Rs. 1.7 billion in FY 06. This decrease was on account of significant decline in prices of omeprazole and amlodipine partially offset by increase in volumes.
  - Revenues from Spain at Rs. 61 million.
- During the year, the Company had a total of 33 filings (including 9 partner products), taking the total filings to 104. Total of 69 ANDAs pending at the USFDA addressing an innovator sales of \$ 57 billion as per IMS December 2006. During the year, the company also received 19 approvals including tentative approvals.

### Branded Formulations - International

- Revenues at Rs 12.3 billion, an increase of 24% over FY06. The growth was primarily driven by the performance of Russia, Romania, Venezuela & CIS markets.
- Revenues in Russia increase by 35% to 3.5 billion as against Rs 2.6 billion in FY06. This growth was primarily driven by increase in sales from key brands of Omez, Cetrine, Nise and Keterol.
  - Market ranking improved to 15<sup>th</sup> position in the retail segment from 24<sup>th</sup> position in the last 12 months (Source: Pharmexpert MAT March 2007)
  - As of MAT March 2007, in the retail segment, the company recorded 36.5% growth as against the market growth of 23.7%. (Source: Pharmexpert MAT March 2007, retail segment)
- Revenues in the CIS markets increase by 35% to Rs 1,118 million as against Rs 827 million in FY07. This growth was primarily driven by increase in sales from Ukraine and Kazakhstan.
- Revenues in RoW markets increase by 25% to Rs 915 million as against Rs 731 million in FY06. The growth was primarily driven by increase in sales from Venezuela, Jamaica South Africa, and Myanmar partially offset by decrease in Vietnam.
- Revenues in Central and Eastern Europe grew by 46% to Rs 377 million as against Rs 259 million in FY06. This growth was driven by significant increase in revenues from Romania.

### Geographic Mix

(in million)

Country	FY07 \$	FY07 INR	As a %	FY06 \$	FY06 INR	as a %	Growth%
Russia	81	3,494	59	60	2,583	59	35
CIS	26	1,118	19	19	827	19	35
Europe (Central & Eastern)	9	377	6	6	259	6	46
ROW	21	915	16	17	731	16	25
<b>Total</b>	<b>137</b>	<b>5,904</b>	<b>100</b>	<b>100</b>	<b>4,400</b>	<b>100</b>	<b>34</b>

## Branded Formulations - India

- Revenues in India increased by 16% to Rs 6.4 billion in FY07 from 5.5 billion in FY06.
  - The Company is ranked the fastest growing company among the Top 10 companies in terms of prescription growth as per CMARC November 2006 to February 2007 report.
  - As per ORG IMS MAT March 2007, the Company is ranked the 2nd fastest growing company in the Top 10 growing ahead of the industry growth rate
- Growth was primarily driven by growth in key brands of Omez, Nise, Stamlo and Razo.
  - As per ORG IMS MAT March 2007, the key brands of Omez and Nise recorded a growth rate of 13.4% and 31.7% respectively as against market growth rate of 3.8% and 17.4% respectively.
- New products launched during the year, totaling 21, contributed Rs.247 million in revenues in FY07.
  - Leon (Levofloxacin), is ranked 6<sup>th</sup> among all the new product introductions in the last 12 months as per ORG IMS MAT 2007.
  - New product launches in the last 3 years have contributed 21% to total revenues during the year.

## Branded Formulations – India - Revenues by Therapies

(in million)

Therapeutic Segment	FY07			FY06			Growth %
	USD Mn	Rs Mn	as a %	USD Mn	Rs Mn	as a %	
Gastro Intestinal	30	1,288	20	24	1,036	19	24
Cardiovascular	28	1,223	19	25	1,093	20	12
Pain	22	968	15	18	781	14	24
Paediatrics	14	607	9	12	520	9	17
Diabetic Care	11	480	7	11	458	8	5
Anti Infectives	9	368	6	7	296	5	24
Nutraceuticals	8	324	5	7	313	6	4
Dermatology	7	281	4	6	263	5	7
Dental	5	235	4	5	220	4	7
Urology	5	214	3	4	169	3	27
Respiratory	4	172	3	3	140	3	23
Women's Health Care	3	127	2	3	124	2	2
Surgery	3	123	2	3	112	2	10
Nephrology	0	4	-	-	-	-	-
<b>Total</b>	<b>149</b>	<b>6,415</b>	<b>100</b>	<b>128</b>	<b>5,526</b>	<b>100</b>	<b>16</b>

**Branded Formulations – India - Revenues by Key brands***(in million)*

Brand	FY07			FY06			Growth%
	USD Mn	Rs Mn	as a %	USD Mn	Rs Mn	as a %	
Nise	20	873	14	17	736	13	19
Omez	19	830	13	16	691	13	20
Stamlo	9	370	6	8	340	6	9
Stamlo Beta	6	268	4	6	263	5	2
Razo	5	211	3	3	127	2	66
Atocor	4	189	3	4	167	3	13
Enam	4	174	3	4	173	3	1
Reclimet	3	138	2	3	124	2	12
Clamp	3	135	2	3	118	2	14
Mintop	3	119	2	3	109	2	9
Others	72	3,109	48	62	2,677	48	16
<b>Total</b>	<b>149</b>	<b>6,415</b>	<b>100</b>	<b>128</b>	<b>5,526</b>	<b>100</b>	<b>16</b>

**Custom Pharmaceutical Services (CPS)**

Revenues from CPS increased to Rs 6.6 billion in FY07 from Rs 1.3 billion in FY06.

- Revenues from the acquisition in Mexico at Rs. 5,397 million in FY07 as compared to Rs. 805 million in FY 06, which also includes three months revenues from Mexico (starting 31<sup>st</sup> Dec 2006)
- Excluding contribution from the acquisition, revenues increased from Rs. 522 million in FY 06 to Rs. 1,203 million in FY 07, driven by growth in customer base and product portfolio.

**Income Statement Highlights**

- Gross profit increased to Rs. 30.9 billion in FY07 from Rs. 11.9 billion in FY06. Gross profit margins on total revenues at 47% as against 49% in FY 06. Revenues from authorized generics contributed 24% to total revenues and earned gross margin significantly below company average gross margin. Decline in Gross Margin % to sales on account of AG products was partially offset by high margin revenues in key product launches of ondansetron and fexofenadine.
- R&D investments (net) at 4 % of total revenues in FY07 as against 9% in FY06. Gross R&D investments increased by 29% to Rs 3.3 billion as against Rs 2.6 billion in FY 06. During the year, the Company recognized Rs 826 million under its R&D partnerships as a benefit to the R&D line item as compared to Rs. 405 million recognized in FY 06.
- Selling, General & Administration (SG&A) expenses increased by 75% to Rs 14.1 billion. This increase is primarily on account of consolidation of the two acquisitions. As % to revenues adjusted for authorized generics and ondansetron, SG&A has lowered to 30% from 33% in FY06.



- Other expense (net) was at Rs 662 million in FY07 as against other income (net) of Rs 534 million in FY06. This is primarily on account of net interest expense of Rs.1,054 million in FY07 as against net interest income of Rs. 419 million in FY06. This is primarily on account of the full year effect of the long-term obtained in March 2006.
- Write down of intangible amounting to Rs. 1,770 million comprising :
  - Write down of Rs. 214 million of Trigenesis intangible assets.
  - Write down of Rs. 1,557 million of product related intangibles at betapharm.
- Amortization was Rs. 1,571 million as compared to Rs. 420 million in FY 06. This includes Rs. 1,302 million relating to intangibles in betapharm, Spain (acquisition of products) and acquisition in Mexico.
- Net income at Rs 9.3 billion (14% of total revenues) as against Rs 1.6 billion (7% of total revenues) in FY06. This translates to a diluted EPS of Rs 58.56 as against Rs 10.62 in FY 06.
- During FY07, the Company generated cash flow from operations of Rs.11.8 billion.
- During FY07, the Company incurred capital expenditure (net) of Rs 4,393 million

all figures in millions, except EPS

All dollar figures based on convenience translation rate of 1USD = Rs 43.10

## Q4 FY07 Financial Snapshot

Extracted from the Unaudited Income Statement for the year ended March 2007

	Q4 FY07			Q4 FY06			
	(\$)	(Rs.)	%	(\$)	(Rs.)	%	Growth %
<b>Particulars</b>							
<b>Total Revenues</b>	<b>361</b>	<b>15,573</b>	<b>100</b>	<b>161</b>	<b>6,932</b>	<b>100</b>	<b>125%</b>
Cost of revenues	135	5,818	37	94	4,037	58	44%
<b>Gross profit</b>	<b>226</b>	<b>9,755</b>	<b>63</b>	<b>67</b>	<b>2,895</b>	<b>42</b>	<b>237%</b>
Selling, General & Administrative Expenses	80	3,433	22	53	2,292	33	50%
R&D Expenses <sup>(1)</sup>	20	852	5	16	678	10	26%
Amortization Expenses	10	451	3	4	162	2	178%
Write down of Intangible	41	1,770					
Other operating (income)/expense net <sup>(2)</sup>	1	25	0	0	4	0	NC
<b>Operating income before forex loss/(gain)</b>	<b>75</b>	<b>3,224</b>	<b>21</b>	<b>(6)</b>	<b>(241)</b>	<b>(3)</b>	<b>NC</b>
Forex Loss/ (Gain)	(5)	(205)	(1)	0	19	0	NC
<b>Operating income/(loss)</b>	<b>80</b>	<b>3,429</b>	<b>22</b>	<b>(6)</b>	<b>(260)</b>	<b>(4)</b>	<b>NC</b>
Equity in loss of affiliates	1	29	0	1	49	1	-41%
Other expenses/(income) net	(3)	(113)	(1)	0	(12)	0	NC
<b>Income before income taxes and minority interest</b>	<b>82</b>	<b>3,513</b>	<b>23</b>	<b>(7)</b>	<b>(297)</b>	<b>(4)</b>	<b>NC</b>
Income tax (benefit)/expense	6	260	2	(1)	(61)	(1)	NC
Minority interest	0	1	0	0	1	0	0%
<b>Net income</b>	<b>75</b>	<b>3,252</b>	<b>21</b>	<b>(5)</b>	<b>(237)</b>	<b>(3)</b>	<b>NC</b>
<b>DEPS</b>							
Exchange rate		43.10			43.10		

- (1) Nil Income recognition under Generics R&D partnership with ICICI venture in Q4 FY 07 as against Rs. 60 million in Q4 FY 06. Reimbursement of expenses from Perlecan Pharma Private Limited of Rs. 85 million in Q4 FY 07

## Revenue Mix by Geography

(in million)

	Q4 FY07 \$	Q4 FY07 INR	as a %	Q4 FY06 \$	Q4 FY06 INR	as a %	Growth %
<b>APIs</b>	<b>90</b>	<b>3,891</b>	<b>25</b>	<b>49</b>	<b>2,091</b>	<b>30</b>	<b>86</b>
India	11	467	12	13	547	26	(15)
International	79	3,424	88	36	1,544	74	122
<b>Branded Formulations</b>	<b>64</b>	<b>2,743</b>	<b>18</b>	<b>48</b>	<b>2,080</b>	<b>30</b>	<b>32</b>
India	34	1,479	54	29	1,269	61	17
International	29	1,264	46	19	811	39	56
<b>Generics</b>	<b>155</b>	<b>6,693</b>	<b>43</b>	<b>37</b>	<b>1,574</b>	<b>23</b>	<b>325</b>
<b>Emerging Business</b>	<b>5</b>	<b>194</b>	<b>1</b>	<b>4</b>	<b>164</b>	<b>2</b>	<b>18</b>
<b>Custom pharmaceutical services</b>	<b>45</b>	<b>1,945</b>	<b>12</b>	<b>24</b>	<b>1,037</b>	<b>15</b>	<b>88</b>
<b>Others</b>	<b>2</b>	<b>107</b>	<b>1</b>	<b>0</b>	<b>(14)</b>	<b>0</b>	
<b>Total</b>	<b>361</b>	<b>15,573</b>	<b>100</b>	<b>162</b>	<b>6,932</b>	<b>100</b>	<b>125</b>

## Revenue Mix by Segment

(in million)

	Q4 FY07 \$	Q4 FY07 INR	As a %	Q4 FY06 \$	Q4 FY06 INR	as a %	Growth %
India	49	2,123	14	45	1,918	28	11
North America	172	7,402	48	35	1,529	22	384
Russia	16	700	4	9	409	6	71
Europe	79	3,414	22	37	1,584	22	116
Others	45	1,934	12	35	1,492	22	30
<b>TOTAL</b>	<b>361</b>	<b>15,573</b>	<b>100</b>	<b>161</b>	<b>6,932</b>	<b>100</b>	<b>125</b>

## Business Highlights

- Revenues at Rs 15.6 billion as against Rs 6.9 billion in Q4 FY06. YoY growth of 125%.
- Excluding revenues from ondansetron and acquisitions, revenues grew by 53% to Rs. 10.5 billion in Q4 FY07.
- Revenues in the API business increased by 86% to Rs. 3.9 billion in Q4 FY07 as against Rs 2.1 billion in Q4 FY06 driven by sales of key products of sertraline and rabeprazole.
- Ondansetron launched in Dec 2006 (under 180 day exclusivity) contributed Rs. 2.7 billion in revenues.
- Revenues in Russia increased to Rs. 700 million in Q4 FY07 from Rs. 409 million in Q4 FY06. This increase was driven by key brands of Nise, Omez and Cetrine.
- Revenues in India increased to Rs. 2.1 billion in Q4 FY07 from Rs.1.9 billion in Q4 FY06. The increase was driven by increase in sales of key brands.

- Revenues from CPS increased to Rs 1.9 billion in Q4 FY07 from Rs 1.0 billion in Q4 FY 06. A substantial part of this growth was driven by sales from Mexico.

### **Income Statement Highlights**

- As a share of revenues, the gross profit ratio increased to 63% of revenues in Q4FY07 from 42% in Q4 FY06. This is relatively higher compared to the previous quarters as well. The significant expansion in the margins for the quarter was largely driven by the high margins enjoyed by ondansetron during exclusivity as well as higher margins in the API and CPS businesses. Further, in the previous quarters, the Company recorded significant sales from authorized generics products which earned significantly lower margins resulting in lower margins at the company level.
- Selling, General and Administration (SG&A) expenses increase by 50% to Rs 3.4 billion. This compares with the 125% growth in revenues.
- R&D investments increased by 26% to Rs 852 million as against Rs 678 million in Q4 FY06. As a share of revenues, R&D expenditure is at 5% as against 10% in Q4 FY06. During the quarter, the Company recognized Rs 85 million under its R&D partnerships as a benefit to the R&D line item as compared to Rs. 60 million recognized in Q4 FY 06.
- Write down of intangibles of Rs. 1,770 million.
- Amortization at Rs.451 million compared to Rs 162 million in Q4 FY 06. Current quarter includes Rs. 387 million relating to intangibles in betapharm, Spain (acquisition of products) and acquisition in Mexico.
- Net income at Rs 3,252 million as against net loss of Rs 237 million in Q4 FY06.

For further queries, please contact the IR desk at:

**Nikhil Shah**

Mail: [nikhilshah@drreddys.com](mailto:nikhilshah@drreddys.com)

Ph: +91-40-66511532